Oslo biotech finds an­oth­er merg­er part­ner af­ter share­hold­ers re­ject­ed No­vem­ber of­fer

Share­hold­ers of Nordic Nanovec­tor did not like the first merg­er part­ner the Nor­we­gian biotech chose last fall. So the com­pa­ny went back to the draw­ing board and has found a new one: Thor Med­ical.

Nordic Nanovec­tor had orig­i­nal­ly planned to com­bine with APIM Ther­a­peu­tics, but a few weeks af­ter the No­vem­ber dis­clo­sure, share­hold­ers de­cid­ed it was a no-go.

This time around, Nordic Nanovec­tor hopes to com­bine with the small, pri­vate Thor Med­ical, which is work­ing on pro­pri­etary tech to make ra­dionu­clides, in­clud­ing al­pha-par­ti­cle emit­ters that it plans to sup­ply to ra­dio­phar­ma com­pa­nies for can­cer ther­a­peu­tics. By its count, more than 50 such star­tups and bio­phar­ma com­pa­nies are work­ing on can­cer ra­dio­ther­a­py, and it ex­pects to make a fi­nal de­ci­sion on an in­dus­tri­al-scale man­u­fac­tur­ing fa­cil­i­ty in 2025.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER